Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing
出版年份 2023 全文链接
标题
Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing
作者
关键词
-
出版物
TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume -, Issue -, Pages 1-8
出版商
S. Karger AG
发表日期
2023-10-26
DOI
10.1159/000534273
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
- (2022) Tailong Qu et al. Biomarker Research
- Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
- (2022) Btissam Chami et al. TRANSFUSION
- Impact of new myeloma agents on the transfusion laboratory
- (2021) Andrew D. Jones et al. PATHOLOGY
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
- (2021) Nehal J Lakhani et al. LANCET ONCOLOGY
- The CD47-SIRPα Immune Checkpoint
- (2020) Meike E.W. Logtenberg et al. IMMUNITY
- Assessing and mitigating the interference of ALX148 , a novel CD47 blocking agent, in pretransfusion compatibility testing
- (2020) Tae Yeul Kim et al. TRANSFUSION
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia
- (2019) C.K. Brierley et al. TRANSFUSION
- Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
- (2019) Robyn J. Puro et al. MOLECULAR CANCER THERAPEUTICS
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
- (2018) Steven E. Kauder et al. PLoS One
- Monoclonal anti-CD47 interference in red cell and platelet testing
- (2018) Randall W. Velliquette et al. TRANSFUSION
- The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
- (2017) Hanke L. Matlung et al. IMMUNOLOGICAL REVIEWS
- How do I work up pretransfusion samples containing anti-CD38?
- (2017) Waseem Q. Anani et al. TRANSFUSION
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Interference of New Drugs with Compatibility Testing for Blood Transfusion
- (2016) Michael F. Murphy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resolving the daratumumab interference with blood compatibility testing
- (2015) Claudia I. Chapuy et al. TRANSFUSION
- Functions and molecular mechanisms of the CD47–SIRPα signalling pathway
- (2009) Takashi Matozaki et al. TRENDS IN CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started